CBT-004已在美國完成臨床2期的首位病人入組

We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause […]

臨床試驗取得顯著進展：CBT-009和CBT-004

We are proud to announce that  CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test […]

醫藥使我們能更好的視覺享受生活

Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision is not just a sense but a gateway to a more fulfilling life. We strive to empower individuals by improving their vision and reducing the burden of eye disease. Through […]

Cloudbreak: 致力於改善視力健康的臨床階段公司

Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story with you. Cloudbreak is a clinical-stage biotechnology company on a mission to improve the vision quality of people worldwide. We aim to help them see life better through medicine by […]

撥康視雲入選2023年中國潜在獨角獸企業

  On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one of the potential unicorn companies in China. The report showed that Suzhou ranked third in the country and first in the province in terms of number of potential unicorns with […]

撥康視雲與眼視覺研究中心在香港簽署戰略合作備忘錄

On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at the Asia Summit on Global Health (ASGH) in Hong Kong. The parties intend to explore opportunities to collaborate on research in ocular science and have reached a preliminary understanding of […]